Imagion Biosystems（IBXX.F）株式概要イマジオン・バイオシステムズ社は、磁気共鳴を利用した医療用イメージング技術を提供している。 詳細IBXX.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去1年間で株主の希薄化は大幅に進んだ マイナスの株主資本 収益が 100 万ドル未満 ( A$73K )+2 さらなるリスクすべてのリスクチェックを見るIBXX.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0119.9k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-12m5m2016201920222025202620282031Revenue AU$59.5kEarnings AU$8.0kAdvancedSet Fair ValueView all narrativesImagion Biosystems Limited 競合他社Nexalin TechnologySymbol: NasdaqCM:NXLMarket cap: US$12.4mBiomericaSymbol: NasdaqCM:BMRAMarket cap: US$7.5mHeartSciencesSymbol: NasdaqCM:HSCSMarket cap: US$5.7mScientific IndustriesSymbol: OTCPK:SCNDMarket cap: US$9.1m価格と性能株価の高値、安値、推移の概要Imagion Biosystems過去の株価現在の株価AU$0.0152週高値AU$0.0452週安値AU$0.01ベータ-0.191ヶ月の変化0%3ヶ月変化-23.08%1年変化25.00%3年間の変化-98.75%5年間の変化-99.86%IPOからの変化-99.58%最新ニュースお知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 08Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Aug 01Imagion Biosystems Limited Announces Board ChangesImagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office).お知らせ • May 06Imagion Biosystems Limited, Annual General Meeting, May 31, 2024Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters.お知らせ • Jan 15+ 1 more updateImagion Biosystems Limited Announces Departure of Isaac Bright as CEOImagion Biosystems Limited informed the market that CEO, MD has resigned to pursue other opportunities effective January 15th, 2024.お知らせ • Nov 15Imagion Biosystems Limited Approves Election of Isaac Bright as DirectorImagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright.お知らせ • Jul 17+ 1 more updateImagion Biosystems Limited Appoints Robert Proulx as Non-Executive ChairmanImagion Biosystems Limited announced that Robert Proulx is transitioning from his roles as President and CEO, and will be staying on as Non-Executive Chairman of the Board. This completes the leadership restructuring plan announced on 28 April 2023, which initiated the process to separate the role of the Chair from the role of CEO. To effect his transition to Non-Executive Chairman, the Company and Mr. Proulx by way of mutual consent ceased Mr. Proulx's employment under his previous roles, effective 20 June 2023. Mr. Proulx is assisting the incoming CEO, Dr Isaac Bright, from 20 June 2023 to 31 July 2023 to allow for a streamlined transition period for the Company. During this handover period (finishing on 31 July 2023), Mr. Proulx will receive a total payment commensurate to 60% of the base salary as specified in his most recent employment agreement (and as outlined in the annexure to this announcement). From 1 August 2023 Mr. Proulx will revert to a Chairman's fee of $63,000 per annum. Mr. Proulx commenced as Non-Executive Chairman on 20 June 2023. The key terms of his From the period of 20 June 2023 to 31 July 2023, Mr. Proulx will be paid at a rate of 60% of his base annual salary as specified in his most recent employment agreement (which equates to an annualized salary of $192,000 being 60% of $320,000). Mr. Proulx's appointment as Non-Executive Chairman of the Board may be terminated at any me in accordance with the provisions of the Company Constitution or the provisions of any applicable law. On any termination, no fee will be payable to Mr. Proulx in respect of any unexpired on of the term of his appointment.お知らせ • Jun 19Imagion Biosystems Limited Announces CEO ChangesImagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board.株主還元IBXX.FUS Medical EquipmentUS 市場7D0%-3.5%1.5%1Y25.0%-22.1%28.6%株主還元を見る業界別リターン: IBXX.F過去 1 年間で-22.1 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: IBXX.Fは、過去 1 年間で28.6 % のリターンを上げたUS市場を下回りました。価格変動Is IBXX.F's price volatile compared to industry and market?IBXX.F volatilityIBXX.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.5%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%安定した株価: IBXX.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のIBXX.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2016n/an/aimagionbiosystems.comImagion Biosystems Limited は磁気共鳴を利用した医療イメージング技術を提供。ナノテクノロジー事業、バイオテクノロジー事業、がん診断事業を展開。同社は、HER2乳がん治療薬としてフェーズ1を完了したMagSenseを開発し、前立腺がんや卵巣がんの研究開発プログラムも進めている。また、がんを検出する酸化鉄ナノ粒子PrecisionMRXも開発している。同社はシーメンスMRIと提携し、MagSense HER2イメージング剤の第2相試験をサポートしている。Imagion Biosystems Limitedは2016年に法人化され、オーストラリアのサウスメルボルンを拠点としている。もっと見るImagion Biosystems Limited 基礎のまとめImagion Biosystems の収益と売上を時価総額と比較するとどうか。IBXX.F 基礎統計学時価総額US$5.64m収益（TTM）-US$3.10m売上高(TTM)US$52.50k107.5xP/Sレシオ-1.8xPER（株価収益率IBXX.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IBXX.F 損益計算書（TTM）収益AU$73.03k売上原価AU$2.10m売上総利益-AU$2.03mその他の費用AU$2.28m収益-AU$4.31m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0088グロス・マージン-2,779.05%純利益率-5,900.86%有利子負債／自己資本比率-122.9%IBXX.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/30 20:27終値2026/04/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imagion Biosystems Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.
お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.
お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.
お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.
お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.
お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.
お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.
お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.
お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 08Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Aug 01Imagion Biosystems Limited Announces Board ChangesImagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office).
お知らせ • May 06Imagion Biosystems Limited, Annual General Meeting, May 31, 2024Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters.
お知らせ • Jan 15+ 1 more updateImagion Biosystems Limited Announces Departure of Isaac Bright as CEOImagion Biosystems Limited informed the market that CEO, MD has resigned to pursue other opportunities effective January 15th, 2024.
お知らせ • Nov 15Imagion Biosystems Limited Approves Election of Isaac Bright as DirectorImagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright.
お知らせ • Jul 17+ 1 more updateImagion Biosystems Limited Appoints Robert Proulx as Non-Executive ChairmanImagion Biosystems Limited announced that Robert Proulx is transitioning from his roles as President and CEO, and will be staying on as Non-Executive Chairman of the Board. This completes the leadership restructuring plan announced on 28 April 2023, which initiated the process to separate the role of the Chair from the role of CEO. To effect his transition to Non-Executive Chairman, the Company and Mr. Proulx by way of mutual consent ceased Mr. Proulx's employment under his previous roles, effective 20 June 2023. Mr. Proulx is assisting the incoming CEO, Dr Isaac Bright, from 20 June 2023 to 31 July 2023 to allow for a streamlined transition period for the Company. During this handover period (finishing on 31 July 2023), Mr. Proulx will receive a total payment commensurate to 60% of the base salary as specified in his most recent employment agreement (and as outlined in the annexure to this announcement). From 1 August 2023 Mr. Proulx will revert to a Chairman's fee of $63,000 per annum. Mr. Proulx commenced as Non-Executive Chairman on 20 June 2023. The key terms of his From the period of 20 June 2023 to 31 July 2023, Mr. Proulx will be paid at a rate of 60% of his base annual salary as specified in his most recent employment agreement (which equates to an annualized salary of $192,000 being 60% of $320,000). Mr. Proulx's appointment as Non-Executive Chairman of the Board may be terminated at any me in accordance with the provisions of the Company Constitution or the provisions of any applicable law. On any termination, no fee will be payable to Mr. Proulx in respect of any unexpired on of the term of his appointment.
お知らせ • Jun 19Imagion Biosystems Limited Announces CEO ChangesImagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board.
